Lakefront Biotherapeutics N.V.
LKFT
NASDAQ Global Select29.28
USD
+0.26
- -
CIK
0001421876
ISIN
US36315X1019
CUSIP
36315X101
Return %
Stock
S&P500
1Y
-8.90
19.01
3Y
-31.88
65.48
5Y
-51.76
72.20
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Henry O. Gosebruch
- Full Time Employees
- 452
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- SchaliEnhoevedreef 20 T Mechelen Belgium 2800
- IPO Date
- May 5, 2005
- CIK
- 0001421876
- Website
- lakefrontbio.com
- Similar Companies
- Business
- Galapagos N.V. (Sponsored ADR: LKFT) engages in the discovery, development, and commercialization of innovative therapies—primarily small molecules and biologics—focused on targeted immune modulation and oncology, with operations centered in Mechelen, Belgium, and an international development footprint. Main products and services - Therapeutic pipelines: TYK2 inhibitors (e.g., GLPG3667) and other small-molecule drug candidates targeting autoimmune and inflammatory diseases; CD19-directed CAR-T programs (GLPG5101, GLPG5201) developed for off-the-shelf or point-of-care manufacture and advancing through early-stage trials; early-stage immunology and hematology programs including next-generation bispecifics and additional small molecules. - Clinical development services: phase I/II clinical trial programs evaluating efficacy, safety, and dosing in autoimmune diseases, dermatology, and hematologic malignancies; biomarker and companion diagnostic development supporting patient stratification. - Strategic collaborations and licensing: ongoing partnerships with major pharmaceutical companies to co-develop and/or out-license assets; collaboration management and data-sharing frameworks to advance programs through clinical milestones. - Portfolio optimization services: prioritization and resource allocation for core assets, with ongoing pipeline discipline to focus on higher-potential indications and to streamline development efforts. Latest major company changes - Corporate reorganization and brand alignment: name change in 2026 to Lakefront Biotherapeutics, with listing and ticker updates on Euronext and NASDAQ (LKFT); consolidation of organizational focus around core assets, streamlined governance, and portfolio prioritization to accelerate development timelines. - Strategic portfolio adjustments: optimization of a CD19 CAR-T portfolio by prioritizing resources toward the most advanced assets and extending development into additional aggressive B-cell malignancies, including Richter transformation of CLL; expansion efforts into double-refractory CLL. - Financing and corporate actions: adoption of a more focused corporate strategy through year 2024–2026, including results-driven updates and business updates tied to quarterly and annual results; management communications outlining strategic shifts and operational refinements in response to pipeline performance. - Product progress and launches: issuance of quarterly and annual results reflecting continued advancement of the pipeline, with emphasis on GLPG5101/GLPG5201 programs and TYK2 inhibitors, and public disclosures of IND-enabling studies for next-generation candidates; ongoing trial enrollments in DM and SLE programs as part of the Forward, Faster initiative. Additional context - Industry and segments: biotechnology with emphasis on immunology, autoimmune and inflammatory diseases, and hematologic oncology; clinical-stage and early commercial potential with strategic alliances underpinning development efforts. - Target markets and customers: global biopharma partners, contract research entities, and future patients in autoimmune diseases, dermatology, and hematologic cancers; physicians and clinical investigators as primary customers for trial enrollment and data generation. - Geographic operations: headquartered in Mechelen, Belgium; development activities and partnerships across North America, Europe, and select other regions; regulatory engagements with EU and US authorities as part of multinational trials. - Founding year and structure: incorporated in 1999; historically operated as a Belgian biotechnology company with multiple collaborations and a broad pipeline; parent-subsidiary dynamics reflect ongoing corporate restructuring to align with Lakefront Biotherapeutics branding. - Subsidiaries and relationships: maintains collaboration agreements with major pharma companies for asset development and commercialization; relationships with contract manufacturers and clinical trial partners to support manufacturing and supply for pipeline programs. Note: This description reflects publicly disclosed, recent information on corporate branding, portfolio strategy, and pipeline evolution through 2026, including the name change to Lakefront Biotherapeutics and associated ticker transition to LKFT. For the most current details, refer to the company’s official communications and exchange disclosures.
Acquisition of Own Shares
Lakefront Announces Paulo Fontoura has Resigned from its Board following his Appointment as Global Head of R&D at Sanofi
Lakefront kondigt het terugtreden van Paulo Fontoura uit de Raad van Bestuur aan na zijn benoeming tot Global Head of Research & Development bij Sanofi
Lakefront Announces Paulo Fontoura has Resigned from its Board following his Appointment as Global Head of R&D at Sanofi
Acquisition of Own Shares
Acquisition of Own Shares
Lakefront Receives Transparency Notification from Madison Avenue Partners
Acquisition of Own Shares
Acquisition of Own Shares
Lakefront Announces Initiation of €50 Million Stock Repurchase Program
Lakefront Appoints Eric Hedrick, MD, as Chief Medical Officer